Medscape Article:
Andrew N. Wilner, MD writes about the recent developments in basic science and clinical medicine to treat some of the impending neurological diseases, including several FDA approval on new drugs, interesting article.
A Look Back: Introduction
2011 has been a very exciting year for neurologists and their patients. Advances in basic science and disciplined clinical trials have led to drug approvals for the prevention of stroke and treatment of epilepsy. In addition, at least 2 oral drugs for relapsing-remitting multiple sclerosis, BG-12 and teriflunomide, boast positive results from phase 3 trials and are poised for approval by the US Food and Drug Administration (FDA).In 2010, the FDA approved dabigatran, a thrombin inhibitor, for anticoagulation in patients with nonvalvular atrial fibrillation. In November 2011, the FDA approved rivaroxaban, a once-daily oral factor Xa inhibitor, for the same indication. Another factor Xa inhibitor, apixaban, recently demonstrated superior results to warfarin in preventing stroke or systemic embolism, with less bleeding and lower mortality, and may soon be approved as well.[1]
Full article at Medscape linked at the top.
